JNJ Johnson & Johnson logo

JNJ Johnson & Johnson

Healthcare
$234.34+1.13%ClosedMarket Cap: $564.11B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

21.44

PEG

0.24

P/B

7.06

P/S

5.85

EV/EBITDA

17.71

DCF Value

$319.62

FCF Yield

3.2%

Div Yield

2.2%

Margins & Returns

Gross Margin

69.1%

Operating Margin

26.9%

Net Margin

21.8%

ROE

26.3%

ROA

10.5%

ROIC

13.6%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$24.06B$5.24B$
Q1 null$24.06B$5.24B$
Q4 null$24.56B$5.12B$
FY null$94.19B$26.80B$

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$250.58

Target (Median)

$252.50

Target Range

$208.00 - $283.00

5 Strong Buy10 Buy10 Hold0 Sell1 Strong Sell
Leerink PartnersOutperform
2026-05-13
StifelHold
2026-04-15
Wells FargoOverweight
2026-04-15
BarclaysEqual Weight
2026-04-15
Morgan StanleyOverweight
2026-04-10

Trading Activity

Insider Trades

View All
REED JOHN Cofficer: EVP, Innovative Medicine, R&D
SellMon May 04
REED JOHN Cofficer: EVP, Innovative Medicine, R&D
SellMon May 04
Woods Eugene A.director
SellMon Apr 27
West Nadjadirector
SellMon Apr 27
WEINBERGER MARK Adirector
SellMon Apr 27

Congress Trades

View All
Ro KhannaBuy
Wed May 13
Thomas H. KeanSell
Tue Apr 14
John BoozmanSell
Tue Apr 14
Ro KhannaSell
Thu Apr 09
Ro KhannaBuy
Thu Apr 09

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - General

Country

US

Exchange

Beta

0.26

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Peers